Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Léa Rouxel"'
Autor:
Marie Kostine, Christophe Richez, Thierry Schaeverbeke, Gael Mouterde, Marie-Elise Truchetet, Julien Henry, Rakiba Belkhir, Vincent Germain, Isabelle Bonnet, Chi Duc Nguyen, Thao Pham, Claire Brière, Léa Rouxel, Thierry Cardon, Fanny De La Fuente, Pierre Edouard Gavand, Céline Labadie, Ambre Lauret
Publikováno v:
RMD Open, Vol 8, Iss 2 (2022)
Objective There is limited experience regarding the use of biological disease-modifying antirheumatic drug (bDMARD) and JAK inhibitor (JAKi) for the management of immune checkpoint inhibitors (ICI)-induced inflammatory arthritis. We aimed to assess t
Externí odkaz:
https://doaj.org/article/eed9e3a2d1ea4e8facaa4a0b25a6ee55
Autor:
Fanny De La Fuente, Rakiba Belkhir, Julien Henry, Chi Duc Nguyen, Thao Pham, Vincent Germain, Pierre Edouard Gavand, Céline Labadie, Claire Briere, Ambre Lauret, Thierry Cardon, Gael Mouterde, Isabelle Bonnet, Léa Rouxel, Marie-Elise Truchetet, Thierry Schaeverbeke, Christophe Richez, Marie Kostine
Publikováno v:
RMD open. 8(2)
ObjectiveThere is limited experience regarding the use of biological disease-modifying antirheumatic drug (bDMARD) and JAK inhibitor (JAKi) for the management of immune checkpoint inhibitors (ICI)-induced inflammatory arthritis. We aimed to assess th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9d1b603ed0a321f47d920d6235d4b352
https://pubmed.ncbi.nlm.nih.gov/36270747
https://pubmed.ncbi.nlm.nih.gov/36270747
Autor:
Florent Martin, Amaury Daste, Marie Beylot-Barry, Marie-Elise Truchetet, Julie Lallier, Sorilla Prey, Caroline Dutriaux, Edouard Forcade, Marine Gross-Goupil, Alain Ravaud, Bernard Bannwarth, Christophe Richez, Thierry Schaeverbeke, Nadia Mehsen, Thomas Barnetche, Léa Rouxel, Léa Dousset, R. Veillon, Marie Kostine, Anne Pham-Ledard
Publikováno v:
Annals of the Rheumatic Diseases. 77:393-398
ObjectivesTo evaluate the prevalence and type of rheumatic immune-related adverse events (irAEs) in patients receiving immune checkpoint inhibitors (ICIs), as well as the correlation with tumour response.MethodsThis was a single-centre prospective ob
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7a7e8918031a6ea7670914253689a239
https://doi.org/10.1136/annrheumdis-2017-212257
https://doi.org/10.1136/annrheumdis-2017-212257
Autor:
Thomas Barnetche, Léa Dousset, Remi Veillon, Sorilla Prey, Thierry Schaeverbeke, Nadia Mehsen-Cetre, Alain Ravaud, Marine Gross-Goupil, Amaury Daste, Marie-Elise Truchetet, Caroline Dutriaux, Marie Kostine, Julien Seneschal, Charlotte Domblides, Charlotte Vergnenegre, Christophe Richez, Eleonora Mauric, Edouard Forcade, Léa Rouxel, Marie Beylot-Barry, Bernard Bannwarth, Baptiste Sionneau
Publikováno v:
Oral Presentations.
Background Immune checkpoint inhibitors (ICIs) are revolutionizing the treatment of some advanced cancers. Gut microbiota has emerged as an important component of anti-tumoral response and can also be related to the occurrence of immune-related adver
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a98286995a61626adc9f60cbd0daf4ed
https://doi.org/10.1136/annrheumdis-2019-eular.7470
https://doi.org/10.1136/annrheumdis-2019-eular.7470
Autor:
E. Berard, Sorilla Prey, Caroline Dutriaux, Alain Ravaud, R. Veillon, Léa Dousset, Léa Rouxel, Charlotte Vergnenegre, Julien Seneschal, Amaury Daste, Marie Beylot-Barry, Baptiste Sionneau, T. Schaeverbeke, Charlotte Domblides, Edouard Forcade, Thomas Barnetche, Marine Gross-Goupil, Marie Kostine
Publikováno v:
Annals of the Rheumatic Diseases. 79:1227.2-1227
Background:Description and initial management of rheumatic immune-related adverse-events (irAEs) from cancer immunotherapies have been reported by several groups but to date, few studies have evaluated the long-term outcomes and management of rheumat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c33c75ca466261c5c8b59f65359de3c8
https://doi.org/10.1136/annrheumdis-2020-eular.4366
https://doi.org/10.1136/annrheumdis-2020-eular.4366
Autor:
Sorilla Prey, J. Lallier, R. Veillon, Bernard Bannwarth, Léa Rouxel, Marie-Elise Truchetet, Thomas Barnetche, Caroline Dutriaux, Marie Beylot-Barry, Léa Dousset, Marine Gross-Goupil, Edouard Forcade, F. Martin, Anne Pham-Ledard, Eleonora Mauric, Nadia Mehsen-Cetre, Amaury Daste, Alain Ravaud, Christophe Richez, Marie Kostine, T. Schaeverbeke
Publikováno v:
WEDNESDAY, 13 JUNE 2018.
Background Immune checkpoint inhibitors (ICI) represent a new standard of care for the treatment of selected advanced cancers and are still being investigated in many other tumour types. By enhancing the T-cell activation, a unique spectrum of inflam
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7158df1bccaa10c3c3eebf3864077caf
https://doi.org/10.1136/annrheumdis-2018-eular.3783
https://doi.org/10.1136/annrheumdis-2018-eular.3783
Autor:
Marine Gross-Goupil, Christophe Richez, K Marie, Caroline Dutriaux, Anne Pham-Ledard, Bernard Bannwarth, Nadia Mehsen-Cetre, Marie Beylot-Barry, T. Schaeverbeke, Léa Rouxel, Sorilla Prey, F. Martin, R. Veillon
Publikováno v:
Poster Presentations.
Background Immune checkpoint inhibitors (ICI) targeting cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and programmed cell death protein 1 (PD-1) axis have been a major advance in cancer immunotherapy. By enhancing T cell activity, unprecedente
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::035023782ae5ec2a79395a679a9cf80b
https://doi.org/10.1136/annrheumdis-2017-eular.6703
https://doi.org/10.1136/annrheumdis-2017-eular.6703